股票代码：600381 股票简称：ST 春天 公告编号：2024-055 青海春天药用资源科技股份有限公司 关于全资子公司收到《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青海春天药用资源科技股份有限公司（以下简称"公司"）子公司西藏春天酒业有 限公司于近日收到西藏自治区市场监督管理局（以下简称"西藏市监局"）藏市监处罚 [2024]10 号《行政处罚决定书》。现将有关内容公告如下： 一、《行政处罚决定书》的主要内容 1.当事人 名称：西藏春天酒业有限公司 统一社会信用代码：91540091MA6T3CWU2R 3. 处罚的法律依据及处罚结果 依据《中华人民共和国反不正当竞争法》第二十条第一款的规定，参照《市场监 管总局关于规范市场监督管理行政处罚裁量权的指导意见》（国市监法规[2022]2 号） 第十条（四），以及《西藏自治区市场监督管理行政处罚裁量权适用规则及裁量基准》 的规定，责令当事人停止上述违法行为，并决定实施行政处罚如下：决定处罚款人民 币 1300000 元（大写：壹佰叁拾万元整）。 ...

经公司核实，公司在 2024 年 6 月 26 日实施回购的过程中，于 14 点 57 分至 15 点 收盘集合竞价期间进行回购股份的委托，累计成交 10 万股，成交价格 1.94 元/股，成 交总金额 19.40 万元。该回购操作系公司回购操作工作人员经验不足、操作失误所致， 并非主观故意违反《上海证券交易所上市公司自律监管指引第 7 号—回购股份（2023 年 12 月修订）》第十九条（二）的规定，也不存在利用回购股份操纵公司股价或进行利 益输送的情况。公司已高度重视上述事项发生的原因，将加强对有关工作人员的培训 及考核，确保后续各项工作遵守有关法律、法规和规范性文件的要求，并对由此给投资 者造成的不便致以歉意。 股票代码：600381 股票简称：ST 春天 公告编号：2024-054 青海春天药用资源科技股份有限公司 关于部分股份回购违规的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份的基本情况 青海春天药用资源科技股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召 开第九届董事会第 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥138,382,698.25, representing an increase of 28.82% compared to the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥59,869,921.83, showing a decline from -¥50,590,714.14 in the previous year[14]. - The net cash flow from operating activities was ¥17,330,525.11, a significant improvement from -¥24,470,667.23 in the same period last year[14]. - The total assets at the end of the reporting period were ¥1,253,653,855.19, down 7.77% from ¥1,359,312,015.51 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company decreased by 5.76% to ¥1,192,186,435.83 from ¥1,265,066,305.34[14]. - The basic earnings per share for the first half of 2024 was -¥0.102, compared to -¥0.086 in the same period last year[15]. - The weighted average return on net assets was -4.87%, a decrease of 1.52 percentage points from -3.35% in the previous year[15]. - The company's main business revenue reached 135.50 million RMB, representing a year-on-year growth of 31.27%[17]. - The liquor segment achieved revenue of 50.001 million yuan, representing a year-on-year growth of 45.95%[18]. - The health segment generated revenue of 41.0934 million yuan, a year-on-year decrease of 25.16% due to the normalization of market demand for respiratory system drugs[18]. - The company reported a significant reduction in contract liabilities, down 65.11% to ¥14,086,157.84 from ¥40,378,116.52, indicating a decrease in advance payments received[26]. - The company’s total revenue for the first half of 2024 was approximately CNY 4.10 billion, a significant increase from CNY 73.39 million in the same period of 2023[65]. - The net loss attributable to the parent company for the first half of 2024 was CNY 59.87 million, compared to a loss of CNY 50.59 million in the same period of 2023[64]. Market and Business Strategy - The company has not disclosed any plans for new product development or market expansion in this report[5]. - The company has established a strategic layout for the efficient utilization of Cordyceps, focusing on health food and pharmaceutical products[17]. - The company plans to enhance sales of traditional Chinese medicine products containing Cordyceps, such as Li Fei Pian and Chong Cao Shen Qi Gao[17]. - The liquor business is primarily focused on high-end products, including the "Tinghua" series, which emphasizes health benefits and innovative brewing techniques[17]. - The company has recognized the growing demand for high-quality products in the liquor industry, aligning its business development with market trends[17]. - The company aims to strengthen cooperation with distributors to expand sales channels and improve product quality[22]. - The company plans to strengthen its two main business segments, focusing on the fast-moving consumer goods and health sectors to mitigate ongoing operational risks[34]. - The company is focusing on expanding its market presence and enhancing product development strategies[58]. Risk Management and Governance - The report includes a detailed description of potential external and internal risks faced by the company[3]. - The company has implemented a comprehensive internal governance system to standardize sales practices and support healthy growth[20]. - The company has actively engaged in R&D collaborations with renowned scientists and research institutions to foster long-term development[19]. - The company has implemented measures to reduce carbon emissions by improving energy efficiency and utilizing clean energy[42]. - The company has established a comprehensive emergency plan for environmental incidents, which includes risk assessment and response strategies[41]. - The company has established comprehensive internal governance regulations but acknowledges the need for ongoing improvements to adapt to external changes[33]. - The company is committed to enhancing internal control systems to mitigate ongoing operational risks as highlighted by the auditors[44]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 44,865[50]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 188,615,194 shares, accounting for 32.13% of the total shares[50]. - The second-largest shareholder, Xiao Rong, holds 56,762,789 shares, representing 9.67% of the total shares[50]. - The top three shareholders include Qinghai Spring Medicine Resources Technology Co., Ltd. with 5,436,100 shares, which is 0.93% of the total shares[50]. - The report indicates that there were no changes in the total number of shares or the capital structure during the reporting period[50]. - There are no significant changes in the shareholding structure or any major contracts that have not been disclosed[50]. - The company did not distribute dividends or increase capital reserves in the reporting period[38]. Environmental and Social Responsibility - The company has actively participated in environmental protection activities and promoted ecological awareness among employees[41]. - The company has reported no administrative penalties related to environmental issues during the reporting period[41]. - The company has a solid environmental monitoring system in place, combining automatic and manual monitoring methods[41]. Financial Management - The company maintains a low debt-to-asset ratio, ensuring smooth financing channels and strategic planning[20]. - The company has implemented a self-inspection and rectification process to improve its governance system and sales practices[21]. - The company reported a significant increase in cash flow management, with total cash and cash equivalents at ¥169,567,426.30 at the end of the period[142]. - The company has not reported any significant changes in the status of its financial assets, with no restrictions on the use of funds due to pledges or freezes[142]. - The company continues to focus on improving its credit risk management practices, as evidenced by the significant reversal of bad debt provisions[162]. Research and Development - Research and development expenses rose by 116.5% to ¥7,040,071.04, up from ¥3,251,810.73, mainly due to increased material usage[25]. - The company has successfully upgraded product flavors and consumer value through the "directed component editing" technology applied to aged liquor[19]. - The company has not reported any new significant projects or acquisitions during this period[179]. - The company's intangible assets formed through internal R&D accounted for 0% of the total intangible assets balance[182]. Taxation and Compliance - The company’s subsidiaries benefit from tax incentives, including a reduced corporate income tax rate of 15% for certain encouraged industries in Tibet[141]. - The company’s subsidiaries also enjoy a local tax exemption for enterprises employing over 70% of local residents until December 31, 2025[141]. - The company recorded a total tax payable of CNY 2,712,583.78 at the end of the period, down from CNY 6,905,916.54 at the beginning, representing a decrease of approximately 60.7%[200].

近日有媒体引用青海春天药用资源科技股份有限公司（以下简称"公司"）有 关部门负责人相关产品"不存在质量和食品安全问题"的表述进行报道。相关表述并非 有关市场监督管理部门《行政处罚决定书》的内容，有关《行政处罚决定书》的内容与 产品质量和食品安全问题无关。 公司股票交易在 2024 年 7 月 29 日、30 日、31 日连续 3 个交易日内日收盘价 格涨幅偏离值累计达到 12%，属于股票交易异常波动。截至 2024 年 8 月 1 日收盘，公 司股价剔除大盘整体因素后的实际波动幅度较大，特别提醒广大投资者理性投资，注 意股票二级市场的交易风险。 公司股价剔除大盘整体因素后的实际波动幅度较大，公司特别提醒广大投资者注 意有关的风险，相关提示如下： 股票代码：600381 股票简称：ST 春天 公告编号：2024-053 青海春天药用资源科技股份有限公司 关于股票交易风险提示的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、二级市场交易的风险 公司股票于 2024 年 7 月 29 日、30 日、31 日 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-052 青海春天药用资源科技股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 青海春天药用资源科技股份有限公司（以下简称"公司"）控股股东西藏荣恩科 技有限公司（以下简称"西藏荣恩"）持有我公司 188,615,194 股无限售条件流通股， 占公司总股本的 32.13%。本次办理股份质押业务后，西藏荣恩累计质押数量为 11,362 万股，占其持股总数的 60.24%，占公司总股本的 19.35%。 西藏荣恩及其一致行动人肖融共持有公司股份 245,377,983 股，占我公司总股 本的 41.80%，累计质押数量（含本次）为 14,376 万股，占其持股总数的 58.59%，占公 司总股本的 24.49%。 一、 上市公司股份质押 公司于今日收到控股股东西藏荣恩关于其部分股份质押的通知，现将有关情况公 告如下： | 股东 | 是否为控 | 本次质 | 是否为 | 是否补 | 质押起 | 质押到 | 质权 ...

截至本回函日,我公司不存在其他买卖贵公司股票的情况、不存 在涉及贵公司的应披露而未披露的重大事项,包括但不限于筹划重大 资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 专此回复。 对青海春天药用资源科技股份有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司: 西藏荣恩科技有限公司 对青海春天药用资源科技股份有限公司 《问询函》的回复 青海春天药用资源科技股份有限公司: 贵公司关于股票交易异常波动的《问询函》我公司已收悉。我公 司就该《问询函》所关注事项回复、确认如下： Nort 本人已收到贵司关于股票交易异常波动的《问询函》,并就该《问 询函》所关注事项回复、确认如下: 专此回复。 截至本回复日,本人不存在买卖贵公司股票、不存在涉及贵公司 的应披露而未披露的重大事项,包括但不限于筹划重大资产重组、股 份发行、债务重组、业务重组、资产剥离和资产注入等重大事项。 回复人:肖融 2024年7月 31 日 ...

股票代码：600381 股票简称：ST 春天 公告编号：2024-051 青海春天药用资源科技股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在 2024 年 7 月 29 日、30 日、31 日连续 3 个交易日内日收盘价格涨幅偏离值累计达到 12%，属于 股票交易异常波动。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露 日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 近日有媒体引用公司有关部门负责人相关产品"不存在质量和食品安全问题" 的表述进行报道。相关表述并非有关市场监督管理部门《行政处罚决定书》的内容，有 关《行政处罚决定书》的内容与产品质量和食品安全问题无关。 请广大投资者理性投资，注意股票二级市场的交易风险。 一、股票交易异常波动的具体情况 公司股票交易在 2024 年 7 月 29 日、30 日、31 日连续 3 个交易日内日收盘价格涨 幅偏离值累计达到 1 ...

上 海 证 券 交 易 所 上证公函【2024】0684 号 关于青海春天药用资源科技股份有限公司 2023 年年度报告的信息披露监管问询函 青海春天药用资源科技股份有限公司： 依据《公开发行证券的公司信息披露内容与格式准则第 2 号－ 年度报告的内容与格式》（以下简称《格式准则第 2 号》）、上海证 券交易所行业信息披露指引等规则的要求，我部对你公司 2023 年年 度报告进行了事后审核。根据本所《股票上市规则》第 13.1.1 条规 定，请你公司进一步补充披露下述信息。 1.年报披露，公司 2023 年期末应收账款余额 3295.06 万元，坏 账准备余额 6931.37 万元，计提比例达 67.78%，远超同行业可比公 司；公司期末应收款项融资 3000 万元，均为应收票据融资，公司前 期未开展过相关业务；公司期末预付款项余额 1.99 亿元，其中预付 第一大供应商余额为 1.37 亿元，占比 68.84%，账龄为 1 到 5 年，存 在长期不结算的情况；公司其他应收款期末余额 845.77 万元，公司 未披露其详细情况。 请公司补充披露：（1）分业务列示前 10 大应收账款情况，包括 对象、交易对方实 ...

标题：关于青海春天药用资源科技股份有限公司股价波动有关事项的监管工作函 证券代码：600381 证券简称：ST 春天 监管类型：监管工作函 涉及对象：上市公司,董事,监事,高级管理人员,控股股东及实际控制人 处分日期：2024-07-22 处理事由：就公司近期股价波动相关事项明确监管要求。 ...

标题：关于青海春天药用资源科技股份有限公司股价波动有关事项的监管工作函 证券代码：600381 证券简称：ST 春天 监管类型：监管工作函 涉及对象：上市公司,董事,监事,高级管理人员,控股股东及实际控制人 处分日期：2024-07-22 处理事由：就公司近期股价波动相关事项明确监管要求。 ...